Dasatinib in Chronic Myelogenous Leukemia

To the Editor: According to the findings of Talpaz et al. (June 15 issue), 1 the efficacy and safety profile of dasatinib therapy in patients with Philadelphia chromosome–positive leukemias and resistance to or intolerance of imatinib seem promising. Nevertheless, pleural effusions developed in about 20% of the patients. The authors do not mention how many patients had to undergo thoracentesis or pleurodesis, or whether this complication was dose-dependent. To the Editor: Talpaz et al. reported that dasatinib induces a durable response in a broad range of patients with imatinib-resistant BCR-ABL mutations who have chronic myelogenous leukemia (CML). We describe a novel . . .